MedPath

Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma

Phase 4
Conditions
Lung Metastases
Tumor Necrosis
Interventions
Registration Number
NCT03932071
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Brief Summary

Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors. In addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung metastasis through this study.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Patients with osteosarcoma who were diagnosed with initial pathology and pathology were excluded from lung metastasis or other metastatic lesions by CT and total body emission-computed tomography, and patients with standard chemotherapy were evaluated.
Exclusion Criteria
  • Pulmonary metastasis, pregnancy or lactation, renal insufficiency (creatinine clearance <70 ml/min/1.73 m2), liver dysfunction, obvious oral disease, and unsuitable for bisphosphonate treatment after evaluation, have been found. With diseases that still require hormone therapy, abnormal blood system, heart disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
experimental groupZoledronic Acid-
Primary Outcome Measures
NameTimeMethod
rate of lung metastasis3 year

Discovery the rate of neonatal lung metastases by high-resolution chest CT

rate of tumor recurrence3 year

Local recurrence rate of tumor or rate of distant metastasis

Secondary Outcome Measures
NameTimeMethod
rate of tumor necrosis less than 90%3 year

the rate of patients that postoperative tumor necrosis rate was estimated to be lower than grade III(90%)

Trial Locations

Locations (1)

2nd Affiliated Hospital of Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath